A combination of the on‐treatment FIB‐4 and alpha‐foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir

• DOI: 10.1111/liv.13889
• Publication Date: 2018-05-24T07:39:46Z
• Authors: Hung‐Hsien Chiang; Chuan‐Mo Lee; Tsung‐Hui Hu; Chao‐Hung Hung; Jing‐Houng Wang; Sheng‐Nan Lu; Hsueh‐Chou Lai; Wen‐Pang Su; Chia‐Hsin Lin; Cheng‐Yuan Peng; Chien‐Hung Chen
• Keywords: Entecavir

Abstract Background & Aims This study investigates the long‐term incidences and predictors of developing hepatocellular carcinoma ( HCC ), cirrhotic events mortality in patients receiving entecavir ETV ) therapy. Methods We enrolled 481 nucleos(t)ide analogue‐naïve chronic hepatitis B CHB who had compensated cirrhosis upon entry received monotherapy for >12 months. Results The 8‐year cumulative , liver‐related were 26.5%, 8.62% 10.03% respectively. Multivariate analysis revealed that diabetic mellitus DM higher fibrosis‐4 FIB ‐4) alpha‐foetoprotein AFP levels at 12 months treatment, ‐4 increase from baseline to independent factors . treatment also mortality. cut‐off values 3, 3 5 as well cut‐offs 5, 9 ng/mL optimal predicting during therapy assessed combined risk clinical outcomes. subgroups with low only 5.95%, 1.03% 2.43% was an predictor Conclusion combination is a useful marker development are